Safety profile of the lopinavir/ritonavir combination before and during the SARS-CoV-2 pandemic

INTRODUCTION: When the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic began, there were no effective treatments assessed by clinical trials. In this context, in France, the French Public Health Council issued, from 5 March, 2020, several proposed recommendations for the therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Lory, Pauline, Combret, Sandrine, Michot, Joelle, Veyrac, Gwenaelle, Chouchana, Laurent, Grandvuillemin, Aurélie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. 2022
Materias:
Pharmacovigilance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618454/
https://www.ncbi.nlm.nih.gov/pubmed/36376122
http://dx.doi.org/10.1016/j.therap.2022.10.066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618454/
https://www.ncbi.nlm.nih.gov/pubmed/36376122
http://dx.doi.org/10.1016/j.therap.2022.10.066

Ejemplares similares